LY294002, one of the earliest PI3K inhibitors, suppresses fibroblast proliferation and the production of FN and COL1/3 in pulmonary fibrosis models (Hu et al., 2020; Zhang et al., 2016). Here, PIK3CG is linked to pulmonary fibrosis.